Publications
|
Trojan A, et al: The Effect of Collaborative Reviews of Electronic Patient-Reported Outcomes on the Congruence of Patient- and Clinician-Reported Toxicity in Cancer Patients Receiving Systemic Therapy: Prospective, Multicentre, Observational Clinical Trial.
JMIR 2021;23(8):e29271. |
Electronic patient-reported outcomes (ePRO) are a relatively novel form of data and have the potential to improve clinical practice for cancer patients. In this prospective, multicentre, observational clinical trial, efforts were made to demonstrate the reliability of patient-reported symptoms. The primary objective of this study was to assess the level of agreement between symptom ratings by physicians and patients via a shared review process in order to determine the future reliability and utility of self-reported electronic symptom monitoring.
|
|
Pircher M, et al.: Response to Vemurafenib in metastatic triple negative breast cancer harbouring a BRAF V600E mutation: a case report and electronically captured patient reported outcome (ePROs).
Case Rep Oncol 2021;14:616–621. |
Effective treatment options are still scarce for metastatic triple-negative breast cancers. An increasing interest in the mutational landscape of this disease will facilitate novel therapeutic strategies in a variety of cancers. Here we report the case of a young female patient who developed multiple lung metastasis of a triple-negative breast cancer 2 years after the completion of local therapy. When she progressed after two palliative chemotherapy lines and local electroporation, a next-generation sequencing revealed a BRAF V600E mutation.
|
|
Trojan A, et al.: Consilium smartphone app for real-world electronically captured patient-reported outcome monitoring in cancer patients undergoing anti-PD-L1-directed treatment.
Case Rep Oncol 2020;13:491–496 |
Digital patient monitoring gains importance for quality of clinical cancer care. Our report provides insight into usability and acceptance of a smartphone app for monitoring of electronically captured patient-reported outcomes (ePROs) in patients undergoing immunotherapy. During 3 months, patients with advanced or metastatic PD-L1-positive cancer of the lung, prostate, and bladder who underwent checkpoint immunotherapy were using the Consilium app for standardized and structured electronic reporting of symptoms and therapy side effects.
|
|
Egbring M, et al.: A mobile app to stabilize daily functional activity of breast cancer patients in collaboration with the physician: A randomized controlled clinical trial.
JMIR 2016; 18(9): e238. |
The well-being of breast cancer patients and reporting of adverse events require close monitoring. Mobile apps allow continuous recording of disease-and medication-related symptoms in patients undergoing chemotherapy. The aim of the study was to evaluate the effects of a mobile app on patient-reported daily functional activity in a supervised and unsupervised setting. We conducted a randomized controlled study of 139 breast cancer patients undergoing chemotherapy.
|
|
Trojan A, et al.: Effect of Collaborative Review of Electronic Patient-Reported Outcomes for Shared Reporting in Breast Cancer Patients: Descriptive Comparative Study.
JMIR Cancer. 2021 Mar 17,7(1): e26950 |
Digital monitoring of treatment-related symptoms and self-reported patient outcomes is important for the quality of care among cancer patients. As mobile devices are ubiquitous nowadays, the collection of electronic patient-reported outcomes (ePROs) is gaining momentum. So far, data are lacking on the modalities that contribute to the quantity
and quality of ePROs. The objective of our study was to compare the utilization of two versions of a subsequently employed mobile app for electronic monitoring of PROs. |
Would you like to see how we developed the Consilium Care™ platform?